Yeganeh Reuven 4

What Happened
Yeganeh Reuven, a 10% owner of BiomX, converted Series Y convertible preferred shares into 670,000 shares of common stock (300,000 on 2026-03-11 and 370,000 on 2026-03-13) at a $2.00 conversion price (total cash cost $1.34M). Reuven then sold those 670,000 shares in private transactions at $5.00 per share (sales on 2026-03-12 and 2026-03-13) for total proceeds of $3.35M. The filing also reports two very small derivative-conversion line items (600 and 740 shares) recorded at $0.00 with no cash amount.

Key Details

• Transaction dates and prices:
  • Conversions: 300,000 shares @ $2.00 (3/11) and 370,000 shares @ $2.00 (3/13) — total acquired 670,000 shares, $1,340,000 cost (per F1).
  • Sales: 300,000 shares (3/12) and 370,000 shares (3/13) sold in private transactions @ $5.00 — total proceeds $3,350,000 (per F3).
  • Small derivative entries: 600 shares (3/12) and 740 shares (3/13) recorded at $0.00 (no cash).
• Ownership after transactions: not specified in the provided filing details.
• Footnotes:
  • F1: Conversions were from Series Y Convertible Preferred into common stock at $2.00/share.
  • F2: Reported securities are directly owned by Pyu Pyu Capital, LLC; Reuven is sole member and disclaims beneficial ownership except for pecuniary interest.
  • F3: Sales were private transactions at $5.00/share.
• Filing timeliness: Form 4 filed 2026-03-13 covering transactions 2026-03-11 to 2026-03-13; filing appears timely.

Context
These transactions are conversions of preferred stock into common shares followed by private sales (not open-market trades). Conversions at a fixed conversion price are different from open-market purchases; here Reuven monetized converted shares via private sales. As a reported 10% owner (through an LLC), this is institutional/owner-level activity rather than an executive payroll sale—useful to note for investors tracking insider sentiment but not a direct indicator of company operational decisions.